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Pleocytosisized that pleocytosis, which is a marker of central nervous system (CNS)
inﬂammation, would result in viral genetic equilibration or de-compartmentalization between HIV
populations in the blood and cerebrospinal ﬂuid (CSF), suggesting viral trafﬁcking.
Methods: Study subjects, who started or interrupted their antiretroviral treatment, had viral loads measured
and clonal viral env sequences generated from HIV RNA extracted from paired blood and CSF samples. White
blood counts in CSF were also measured at each timepoint. Degree of inter-compartment segregation was
calculated by posterior probability using linear discriminant analysis and multidimensional scaling. Co-
receptor usage was determined using a trained support vector machine.
Results: Pleocytosis was strongly associated with disruption of viral compartmentalization.
Conclusions: Inﬂammation in the CNS, marked by pleocytosis, allows HIV populations to mix between blood
and CSF, which may increase the overall viral genetic diversity within the CSF.
Published by Elsevier Inc.IntroductionHIV-1 invades the central nervous system (CNS) early during
primary infection, and can cause neurological disease ranging from
minor cognitive and motor disorders to severe dementia. Neuro-
cognitive manifestations of HIV remain a persistent therapeutic
problem in the current era of potent antiretroviral drugs, as 50% of
persons with HIV and CD4 counts b500/ml have at least mild
cognitive impairment and nearly 7% of patients with AIDS develop
HIV associated dementia.
The CNS differs from other tissues in immunological surveillance,
cytokine milieu, target cell characteristics, and antiretroviral penetra-
tion. Such an environment provides a unique reservoir for HIV-1
replication. Viral replication and evolution within the CNS most likely
can lead to mutational adaptation to neuronal tissues, and phyloge-
netic analyses have documented distinct subpopulations in the blood
and CNS compartments. Genetic variants adapted to the CNS may be
the basis of at least some of the HIV associated neurocognitiveiego, 9500 Gilman Drive 0679,
nc.dysfunction (HAND). The causes of HAND are most likely multi-
factorial, and may include direct toxic effects of HIV proteins, cytokine
meditated damage, host genetic susceptibility, added inﬂammatory
effects from other CNS tropic infections, like syphilis, Cryptococcus or
herpes viruses.
To determine how CNS inﬂammation can change the viral
dynamics in the CNS, we investigated how viral genetic compart-
mentalization between blood and CSF changed in the setting of
pleocytosis. Pleocytosis is the appearance of leukocytes in the CSF,
which is used clinically as amarker of meningeal inﬂammation and is
deﬁned as N5 cells/mm3. Pleocytosis can occur intermittently during
HIV-1 infection and most likely reﬂects an interruption of the blood–
brain barrier and trafﬁcking of white blood cells from the blood into
the CSF. We investigated if such a barrier disruption may provide an
opportunity for infected lymphocytes to migrate into the CSF
and thus introduce blood-derived viruses into the CNS. As a result,
we would expect to identify a disruption of viral compartmentaliza-
tion between the CNS and blood during periods of pleocytosis. Using
clonal sequence analysis of HIV RNA viral populations on long-
itudinally collected paired blood and CSF samples, we studied
the relationships between pleocytosis and degree of viral compart-
mentalization and inter-compartment correlation between blood
and CSF.
Fig. 2. Phylogenetic analysis of viral sequences derived from blood and CSF from subject
686 who demonstrated minimal pleocytosis (range 1–7 WBC/ml). Legend: C2–V3 env
sequences derived from blood and CSF of subject 686 remained phylogenetically
distinct when sampled longitudinally over 3 weeks, pb0.01 per Slatkin–Maddison test.
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Study population
All study participants lived in San Diego and reported sex with
men as their only HIV risk factor. The average age of the
participants at enrollment was 47 years (range 34–58 years), the
average CD4 count at study enrollment was 306 cells/ml (range 200
to 461 cells/ml), and none had evidence of active systemic or CNS
opportunistic infections or malignancies during the study. Partici-
pants were sampled either before or after interrupting antiretroviral
therapy (n=3, subjects 839, 409, and 487) or before and after
starting therapy (n=1, subject 686) (Fig. 1). Regimens of antire-
troviral therapy for each participant included at least three
antiretrovirals from two different classes. Although the number of
participants was small in each group, there were no statistical
differences in baseline CD4 or CSF or blood viral loads between
participants who demonstrated minimal (subjects 686) or persistent
(subject 487) pleocytosis or those participants who developed
pleocytosis (subjects 839 and 409) (data not shown).
Association between viral compartmentalization and pleocytosis
Viral compartmentalization was determined using two approaches:
Slatkin–Maddison test, which has been shown to be robust in detecting
within patient compartmentalization of HIV populations and linear
discriminant analysis. In one participant (686) minimal pleocytosis was
demonstrated, viral compartmentalization between the blood and CSF
derived viral populations persisted throughout the study period (Table
1); viral sequences clustered strictly by anatomic compartment and not
by time of sampling by both phylogenetic analysis (Fig. 2) and
multidimensional scaling (Table 1) of clonal env sequences at each
timepoint. Two other participants (subjects 839 and 409) had no
pleocytosis at the beginning of the study period and compartmentaliza-
tion persisted in both the blood and CSF. When pleocytosis developed,
however, the observed compartmentalization was disrupted and wasFig.1. Time course of viral loads in blood and CSF compartments andwhite blood cell counts i
in each subject (numbered ovals). Blood plasma viral loads are represented in open squares, C
(○) and stop (*) of antiretrovirals are labeled.negatively correlated with the level of leucocytes in the CSF for all
sampled timepoints for subject 839 and for the ﬁrst and second
timepoint samples for subject 409. This is exempliﬁed for subject 839 in
Figs. 3A–C. Subject 409 was unique among the study group; he
demonstrated signiﬁcant viral compartmentalization (Slatkin–Maddi-
son test: pb0.001) during a high level of pleocytosis (WBC 101) at the
third time point sampling. This sample was also unique among all
patient samples for CSF viral loads being higher than blood viral loads at
the time of sampling. In one participant (subject 487), leucocytes were
persistently elevated in the CSF after stopping antiretroviral therapy and
during sampling (Table 1). Viral compartmentalization between blood-
and CSF-derived viral isolates was not observed in these samples
(Table 1). Overall, viral compartmentalization was signiﬁcantly asso-
ciated with the level of white blood cells measured in the CSF (p=0.03)n CSF (cells/mm3). Legend: Blood and CSF samples were collected at the three timepoints
SF viral loads in open diamonds, and CSF white blood cell counts in open tiangles. Start
Table 1
Participant characteristics, compartamentalization and intra-compartment genetic diversity
Subject CD4 cells/ml3 at
ﬁrst sampling








686 200 1 4.8 2.6 1 0.01 1.00 4.7 5.0
2 4.7 2.3 1 0.002 1.00 3.0 4.2
3 4.4 2.6 7 0.002 0.99 2.0 0.1
839 293 1 4.0 3.0 3 b0.001 1.00 0.2 0.1
2 3.7 3.6 15 b0.001 0.69 1.0 0.6
3 3.5 2.8 17 N0.1 0.76 1.0 0.6
409 270 1 5.0 1.7 2 b0.001 0.51 1.9 0.9
2 5.4 5.4 27 N0.1 0.51 1.5 0.7
3 5.0 5.3 101 b0.001 0.99 2.8 3.3
487 461 1 5.5 5.1 16 N0.1 0.91 0.7 0.4
2 5.1 5.4 48 N0.1 0.70 1.0 0.4
3 5.0 5.6 185 N0.1 0.78 1.1 0.4
Legend: Slatkin–Maddison values of pb0.05 are in bold and represent viral genetic compartmentalization between CSF and blood viral populations.M values are the medians of the
posterior probabilities for multidimensional scaling; CSF: cerebrospinal ﬂuid.
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amino acid residues were found to vary signiﬁcantly across all
participants between blood and CSF whether or not anatomic
compartmentalization of viral populations was identiﬁed.
Genetic diversity
Viral genetic diversity did not correlate with the degree of
pleocytosis in either the CSF or the blood across patients (pN0.1).
Within subject viral diversity also did not change appreciably in the
blood compartment in relation to CSF WBC for all participants;
however, viral genetic diversity did increase in the CSF in subjects
839 and 409 when pleocytosis developed (pb0.05). Viral genetic
diversity did not change in CSF in relation to the level of CSF WBC
for subject 487, who had relatively high levels of pleocytosis
throughout the sampled timepoints. Subject 686 had a trend in
decreasing diversity during a slight increase in pleocytosis (p=0.07,
1 to 7 cells/ml) (Table 1).
Co-receptor usage
Based on genotypic analysis, all virus isolates from all subjects,
except subject 686, exclusively used the CCR5 co-receptor, regardless
of whether they were derived from the blood or CSF. For subject 686,
viral isolates that used CXCR4 were exclusively found in the third
timepoint blood sample, whereas the viruses in CSF were universally
CCR5-tropic. The CXCR4 viruses from subject 686 clustered together in
maximum likelihood phylogenetic reconstruction (Fig. 2).
Discussion
These investigations demonstrate that CSF pleocytosis is often
associated with the disruption of viral compartmentalization between
the CNS and the blood. This disruption of viral compartmentalization
could be from either immigration of cell-free virus from the blood into
the CSF or from HIV infected lymphocytes themselves migrating into
the CSF from the blood and then releasing their virus. Alternatively,
these results could also be explained by CSF-derived virus migrating
into the blood, although this is unlikely given the much larger viral
population in the blood and the small proportion of blood sampled for
most of timepoints sampled. One notable exception was the third
timepoint sampling from subject 409 that demonstrated CSF viral
loads higher than viral loads found in the blood and was associated
with signiﬁcant viral compartmentalization between the blood and
the CSF. This suggests that there was considerable HIV replication in
the CSF distinct from the blood and perhaps this local CSF replication
was sufﬁciently inﬂammatory to cause the high level of pleocytosis
that was also observed at this timepoint. We also investigated the co-receptor usage among the viral isolates; however, only ﬁve isolates
from the entire study were found to use the CXCR4 co-receptor;
therefore, no ﬁrm conclusions can be made in this study concerning
viral compartmentalization, pleocytosis and co-receptor usage.
CSF pleocytosis represents an increased number of leucocytes in
the CSF and results from meningeal inﬂammation from a wide variety
of bacterial, fungal, parasitic and viral pathogens, including HIV itself.
Three of our study participants developed pleocytosis after the
discontinuation of antiretroviral therapy, which has been documented
previously. Each of these infections can inﬂuence neurocognitive
functioning usually during acute symptomatic episodes of CNS
inﬂammation, and the chronic nature of HIV infection seems to
exert insidious and persistent effects on the CNS often culminating in
symptomatic HAND in the later stages. Possible mechanisms for this
include neuroadaptation and associated neuropathogenicity, and
neuroinﬂammation; however, these processes are not necessarily
exclusive from each other. Pleocytosis may inﬂuence viral neuroa-
daptation and associated neuropathogenicity by trafﬁcking HIV-
infected lymphocytes into the CNS, potentially increasing CNS viral
genetic diversity. Alternatively, increased viral trafﬁcking during
pleocytosis would increase the concentration of viral proteins in the
CNS, which may mediate direct or indirect neurotoxic effects without
genetic changes in the local virus. On the other hand, CSF pleocytosis
and associated disruption of viral compartmentalization may not have
a direct effect on HAND at all, but may only serve as a marker of CNS
inﬂammation, and inﬂammation itself may be the destructive force
that results in HAND. Because of the small number of participants in
this study, HAND was not assessed in relation to pleocytosis or viral
compartmentalization; therefore, it remains unclear to what degree
HAND is associated with persistent or intermittent inﬂammation and
towhat extent CNS inﬂammation is themechanism underlying HAND.
Also, given the small nature of our study, we were unable to assess
other important processes, like stochastic and founder effects and host
immune responses that are likely to inﬂuence the entire gamut of the
inter-related factors of pleocytosis, compartmentalization, intra-host
evolution, neuroadaptation, and neurovirulence; therefore, future
studies such as these are needed to further delineate the mechanisms
of HIV-mediated neuropathogenesis.
Methods
Study participants, specimen collection and clinical data
Paired blood and CSF samples were collected from four male
participants, who were enrolled in longitudinal clinical studies at the
University California San Diego HIV Neurobehavioral Research Center
(HNRC) between years 1997 and 2001. All participants were selected
based on measurements of CSF pleocytosis before or after starting or
207D.M. Smith et al. / Virology 385 (2009) 204–208interrupting antiretroviral therapy (Fig. 2). One participant (subject
686) was selected because he had minimal evidence of pleocytosis
(peak b8 cells/ml of CSF) at all timepoint samples. Two other
participants (subjects 839 and 409) were selected because they
developed pleocytosis at some timepoints (peak 17 and 185 cells/ml of
CSF respectively). One participant (subject 487) was chosen becausehe demonstrated pleocytosis at all timepoint samples (range 16–
185 cells/ml of CSF). None of the patients had evidence of systemic or
CNS opportunistic infections or malignancy based on clinical,
laboratory and neuro-imaging studies. Data were available on past
and present medical therapy, current viral load and CD4 counts, nadir
CD4 counts and CSF cell counts. All studies were conducted in
compliance with local IRB guidelines and with written informed
consents. Paired blood from peripheral venipuncture and CSF from
lumbar punctures were collected and processed within 2 h. Blood
plasma and cell free CSF were aliquoted and frozen and stored at
−80 °C until processing.
HIV RNA extraction and quantitation
HIV RNAwas extracted and quantiﬁed from 500 μl of blood plasma
per manufacturer's protocol (50 copies/ml minimal level of detection;
Amplicor HIV-1 Monitor® Test, Roche Molecular Diagnostics, Plea-
santon, California, USA). HIV RNA was extracted from 1 ml of CSF and
then quantiﬁed (50 copies/ml minimal level of detection; Amplicor
HIV-1 Monitor® Test, Roche Molecular Diagnostics, Pleasanton,
California, USA), as previously described.
env sequencing
Reverse transcription and PCR ampliﬁcation of C2-V3 env for HIV
RNA from each sample was performed in triplicate using the
Finnzyme one step RT-PCR kit (MJ Research), and primers V3Fout
and V3Bout as previously described in a 50 μl reaction volume. 5 μl of
ﬁrst step RT-PCR product was used in the second, nested PCR
reaction with primers V3Fin and V3Bin, Tris pH 8.0, 30 pmol each
primer, 2.5 mM MgCl, 200 μM dNTP, BSA 10 mg/ml in a total volume
of 50 μl. Cycling parameters were: 94 °C×2 min; 94 °C×30 s,
54 °C×30 s, 72 °C×1 min for 35 cycles; 72 °C×10 min. All assays were
conducted in conditions to minimize PCR contamination utilizing
aerosol resistant pipet tips, dedicated PCR reagents and laminar ﬂow
hoods. All assays included negative controls. Blood plasma and CSF
samples were processed separately on different days to minimize
within-patient cross contamination of samples. Nested PCR products
were visualized by agarose gel electrophoresis and ethidium staining.
Replicate PCR products were proportionately pooled and cloned
using the TOPO-TA™ cloning system (Invitrogen, Carlsbad, CA).
Twenty clones were selected by blue white screening and expanded
in 1.5 ml broth cultures. Plasmid clones were puriﬁed using Qiagen
Mini-prep kits (Qiagen, Chatsworth, CA). Puriﬁed plasmids were
sequenced bidirectionally with –20M13 primer (5′-sequence-3′) or
TOPO Forward primer (5′-sequence-3′) using Prism Dye terminator
kits (ABI, Foster City, CA) on an ABI 3100 Genetic Analyzer. Sequences
were initially compiled, aligned, and manually edited using
Sequencher™ 4.0 (Genecodes, Ann Arbor, MI). Preliminary align-
ments were then performed using the MUSCLE package. Generated
alignments were then inspected and further aligned manually using
Bioedit. Sequences are publicly available at Genbank (accession
numbers FJ159856FJ16FJ160261).Fig. 3. (A) Phylogenetic Analysis of viral sequences derived from blood and CSF from
subject 839 who demonstrated no pleocytosis (3 WBC/ml) at timepoint 1. Legend: C2-
V3 env sequences derived from blood (closed circles) and CSF (open circles) of subject
839 were phylogenetically distinct at the ﬁrst timepoint, pb0.01 per Slatkin Maddison
test. (B) Phylogenetic Analysis of viral sequences derived from blood and CSF from
subject 839 who had developed pleocytosis from timepoint 1 (1 WBC/ml) to timepoint
2 (15 WBC/ml). Legend: C2-V3 env sequences derived from blood (closed triangles) and
CSF (open triangles) of subject 839 were not phylogenetically distinct at the second
timepoint, pN0.5 per Slatkin Maddison test. (C) Phylogenetic analysis of viral sequences
derived from blood and CSF from subject 839 where pleocytosis persisted from
timepoint 2 (15 WBC/ml) to timepoint 3 (17 WBC/ml). Legend: C2–V3 env sequences
derived from blood (closed squares) and CSF (open squares) of subject 839 were not
phylogenetically distinct at the third timepoint, pN0.05 per Slatkin–Maddison test.
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Phylogenetic and genetic distance and diversity analysis was
performed using HyPhy (T/T ratio of 2.0, gamma distributed substitu-
tion rate) on clonal sequences for individual subjects and the
timepoint and compartment sampled, and DNADIST and NEIGHBOR
methodswere used to reconstruct the phylogeny of the entire dataset .
Trees were displayed using Treeview. Assessment of degree of inter-
compartment segregation was performed by testing for Panmixis
using gene phylogenies as implemented in MacClade. In brief, from
the maximum likelihood trees for each individual patient's C2V3
sequences and their characterization according to compartment of
origin, the minimum number of intercompartment migration events
allowed by the tree was tallied. This result was compared to the
distribution of migration events for 1000 randomly generated trees.
Evidence of restricted gene ﬂow (compartmentalization) was docu-
mented when b1% (or between 1% and 5%) of the random trees
required the same or a fewer number of migration events as for the
sample data. Genetic diversity analyses were also performed in
relation to the degree of pleocytosis across and within subjects, and
across and within anatomic compartments.
Analysis of sequence differences between CSF and blood virus
Prediction of co-receptor usage was performed using the Wetcat
SVM (support vectormachine), available at: http://spots.ucsd.edu:8080/
wetcat. Residues at which amino acid frequencies varied signiﬁcantly
between compartments were identiﬁed by Monte Carlo approximation
of the Mantel-Haenszel and likelihood ratio tests, based on identity of
individual amino acid or on chemical class of the amino acid residue
(positive, negative, neutral or hydrophobic) with pb0.05 considered to
be signiﬁcant. Residue positions demonstrating intercompartmental
variation by both of these univariate measures were included in a
stepwise logistic regression (with entry cutoff pb0.10 and retention
cutoff pb0.05). Forward logistic regression was performed with the
entry criterion pb0.05. Analyses were performed on the entire dataset
as well as on “pruned” data including only those patients exhibiting
phylogenetic segregation of CSF-and blood-derived sequences veriﬁed
to be signiﬁcant by the Slatkin–Maddison test (pb0.01) and in which
CSF-derived sequences were not intermingledwith signiﬁcant numbers
of blood-derived sequences, i.e. viral compartmentalization was
observed. Residue speciﬁc entropy was computed from the frequency f
(Ai) of amino acid A at position i according to −∑Af(Ai)ln[f(Ai)].
Multidimensional scaling, linear discriminant and statistical analysis
For each patient and timepoint a euclidean distance matrix was
built using intra-patient sequence data, with the aid of the software
package ape. These distance measures were represented in two
dimensions through multidimensional scaling using the software
package MASS. Linear discriminant analyses were further carried out
to classify the viruses as belonging to the blood or the CSF
compartment, and posterior probabilities were calculated for leave-one-out cross-validation, using the package MASS. Subsequent
analyses were performed using the analytical package R. For
parameters such as CD4 count, CSF pleocytosis and viral load, both
parametric (ANOVA and F test) and non-parametric (Kruskal–Wallis
and Wilcoxon Rank) tests were applied after log transformation of
viral load data and square root transformation of CD4 count data.
Signiﬁcance was deﬁned at the pb0.05 level. Statistical analyses were
performed using SAS V8 and JMP IN (SAS Institute, Cary NC).
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